Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis

Bibliography

• Chiricozzi A, Zhang S, Dattola A, et al. New insights into the pathogenesis of cutaneous autoimmune disorders. J Biol Regul Homeost Agents 2012;26(2):165-70
   PubMed Web of Science ®Google Scholar
• Griffths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Lancet 2003;361:1197-204
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondyloarthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1-44
   Google Scholar
• Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 2010;18:297-304
   PubMed Web of Science ®Google Scholar
• Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;324:277-84
   PubMed Web of Science ®Google Scholar
• Kuijpers AL, van de Kerkhof PC. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol 2000;1:27-39
   PubMedGoogle Scholar
• Ortonne J-P, Orzechowski H-D, Rantanen T, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70
   PubMedGoogle Scholar
• Reich K, Burden AD, Eaton JN, et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012;166:179-88
   PubMed Web of Science ®Google Scholar
• Humira (adalimumab) prescribing information [package insert]. Abbott Laboratories IL; North Chicago: 2012
   Google Scholar
• Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis 1999;58(Suppl 1):I70-2
   PubMedGoogle Scholar
• Santora LC, Kaymakcalan Z, Sakorafas P, et al. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001;299:119-29
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• Granneman RG, Zhang Y, Noertersheuser PA, et al. Pharmacokinetic/pharmacodynamics (PK/PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. Arthritis Rheum 2003;48:S140-1
   Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006t;55(4):598-606
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66
   PubMed Web of Science ®Google Scholar
• Vena G A, Galluccio A, De Simone C, et al. A multicenter open-label study experiences on the response of psoriasis to adalimumab and effect of dose escalation in non-responders: the APHRODITE project. Int J Immunopathol Pharmacol 2009;22(1):227-33
   PubMed Web of Science ®Google Scholar
• Thaçi D, Ortonne J P, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patient with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010;163(2):402-11
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis 2009;68:702-9
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Choy E, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010;12(3):R113
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesion. Ann Rheum Dis 2010;69:394-9
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34(5):1040-50
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007;57:269-75
   PubMed Web of Science ®Google Scholar
• Gladman DD, Sampalis JS, Illouz O, Guérette B; ACCLAIM Study Investigators. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010;37(9):1898-906
   PubMed Web of Science ®Google Scholar
• Teoli M, Zangrilli A, Chimenti MS, et al. Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. Clin Dev Immunol 2012;2012:823854
   PubMed Web of Science ®Google Scholar
• Van L, Modi SV, Yang DJ, et al. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Arch Dermatol 2008;144:804-6
   PubMed Web of Science ®Google Scholar
• van Kuijk AW, de Groot M, Stapel SO, et al. Relationship between the clinical response to adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010;69:624-5
   PubMed Web of Science ®Google Scholar
• Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010;24(5):530-4
   PubMed Web of Science ®Google Scholar
• Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, et al. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol 2011;25(5):579-86
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010;12(3):R117
   PubMed Web of Science ®Google Scholar
• Saraceno R, Pietroleonardo L, Mazzotta A, et al. TNF-alpha antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opin Biol Ther 2013;13(4):469-73
   PubMed Web of Science ®Google Scholar
• Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011;165(5):1037-43
   PubMed Web of Science ®Google Scholar
• Piérard GE, Piérard-Franchimont C, Szepetiuk G, et al. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities. Expert Opin Biol Ther 2010;10(8):1197-208
   PubMed Web of Science ®Google Scholar
• Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006;212(2):123-7
   PubMed Web of Science ®Google Scholar
• Papp K, Signorovitch J, Ramakrishnan K, et al. Effects of adalimumab versus placebo on risk of symptoms worsening in psoriasis and subsequent impacts on health-related quality of life. Analysis of pooled data from two randomized, double-blind, placebo-controlled, multicenter clinical trials. Clin Drug Investig 2011;31:51-60
   PubMed Web of Science ®Google Scholar
• Revicki DA, Menter A, Feldman S, et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the united states general population norms: results from a randomized, controlled phase III study. Health Qual Life Outcomes 2008;6:75
   PubMed Web of Science ®Google Scholar
• Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 2012;66:e67-76
   PubMedGoogle Scholar
• Iaconi A, Feldman SR, Balkrishnan R. Psoriasis and its treatment with adalimumb. Expert Opin Biol Ther 2010;10(1):133-52
   PubMed Web of Science ®Google Scholar
• Kimball AB, Bensimon AG, Guerin A, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities. Am J Clin Dermatol 2011;12(1):51-62
   PubMed Web of Science ®Google Scholar
• Linder D, Sampogna F, Torreggiani A, et al. Psodisk, a new visual method for assessing the burden of psoriasis on patients. J Eur Acad Dermatol Venereol 2012;26(9):1163-6
   PubMed Web of Science ®Google Scholar
• Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis. A comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011;12(5):321-37
   PubMed Web of Science ®Google Scholar
• Schmitt J, Wozel G. Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systemic review of the literature. Biologics 2009;3:303-18
   PubMedGoogle Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23.548 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72(4):517-24
   PubMed Web of Science ®Google Scholar
• Joyau C, Veyrac G, Dixneuf V, et al. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012;30(5):700-6
   PubMed Web of Science ®Google Scholar
• De Simone C, Sollena P, Coco V, et al. Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases. G Ital Dermatol Venereol 2013;148(2):175-84
   PubMed Web of Science ®Google Scholar
• Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59(7):996-1001
   PubMed Web of Science ®Google Scholar
• Michaëlsson G, Kajermo U, Michaëlsson A, et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005;153(6):1243-4
   PubMed Web of Science ®Google Scholar
• Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63(2):382-90
   PubMed Web of Science ®Google Scholar
• Nijsten T, Wakkee M. Psocare: Italy shows the way in postmarketing studies. Dermatology 2008;217(4):362-4
   PubMed Web of Science ®Google Scholar
• Sauzullo I, Mengoni F, Scrivo R, et al. Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. Int J Tuberc Lung Dis 2010;14(7):834-40
   PubMed Web of Science ®Google Scholar